LIXTE BIOTECHNOLOGY HOLDINGS, INC.
NMADDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LB-100 | Phase 2 | Ovarian Clear Cell Carcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s (NMAD) pipeline across Phase 2. Its lead program is LB-100 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s next FDA catalyst?→
LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s (NMAD) next tracked catalyst is a Earnings expected November 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NMAD biotech catalysts?→
Add NMAD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.